AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery Technology

December 29, 2019 GMT

MELBOURNE, Australia--(BUSINESS WIRE)--Dec 29, 2019--

Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP ® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers and will be conducted at 4-5 US sites.

The development of AZD0466, is being progressed under a multi-product license whereby Starpharma is eligible to receive development, launch and sales milestones of up to US$124 million, plus tiered royalties on net sales. The first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million. AstraZeneca also funds the development costs of DEP ® AstraZeneca products under the license.

AstraZeneca describes AZD0466 as having the potential to be a ‘best-in-class’ agent in this field with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL 1.

Bcl2 is a clinically validated oncology target with the Bcl2 inhibitor, venetoclax (Venclexta™ - AbbVie/Genentech), being approved by the US FDA in 2016 with estimated peak global sales projected to be between US$2-3 billion 2.

Dr Jackie Fairley, Starpharma CEO, commented: “It is really exciting to achieve this important milestone both for our collaboration with AstraZeneca and for Starpharma’s DEP ® platform. This is our first partnered DEP ® product to enter the clinic, alongside our three internal DEP ® products, DEP ® docetaxel, DEP ® cabazitaxel and DEP ® irinotecan. AZD0466 is a great illustration of the benefits that can be created for novel agents using Starpharma’s DEP ® platform and we look forward to further updates as the trial progresses.”

About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

1 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 presentation
2https://www.fiercepharma.com/pharma/abbvie-roche-drive-venclexta-toward-3b-rituxan-combo-nod-cll

View source version on businesswire.com:https://www.businesswire.com/news/home/20191229005009/en/

CONTACT: Media

WE Worldwide

Rebecca Wilson

+61 417 382 391

rwilson@we-worldwide.comArthur Chan

+61 2 9237 2805

arhurc@we-worldwide.comStarpharma

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

KEYWORD: AUSTRALIA/OCEANIA AUSTRALIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE CARDIOLOGY BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH CLINICAL TRIALS

SOURCE: Starpharma Holdings Limited

Copyright Business Wire 2019.

PUB: 12/29/2019 06:07 PM/DISC: 12/29/2019 06:07 PM

http://www.businesswire.com/news/home/20191229005009/en